{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:11:08Z","timestamp":1792811468183,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euo.2025.12.004","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T20:35:12Z","timestamp":1767818112000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of Causal and Noncausal Components of Screening on Prostate Cancer Mortality: A Mediation Analysis from the Dutch, Finnish, and Swedish Centers of the European Randomized Study of Screening for Prostate Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-6448","authenticated-orcid":false,"given":"Sebastiaan","family":"Remmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Talala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique J.","family":"Roobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Hugosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka","family":"Arnsrud Godtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Nieboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anssi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.12.004_b0005","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.eururo.2015.02.042","article-title":"Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer","volume":"68","author":"Buzzoni","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.004_b0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.004_b0015","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/ijc.24870","article-title":"The effect of study arm on prostate cancer treatment in the large screening trial ERSPC","volume":"126","author":"Wolters","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2025.12.004_b0020","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.eururo.2019.03.010","article-title":"Could differences in treatment between trial arms explain the reduction in prostate cancer mortality in the European Randomized Study of Screening for Prostate Cancer?","volume":"75","author":"Carlsson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.004_b0025","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.12.004_b0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.12.004_b0035","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.euo.2025.12.004_b0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1465-5101.2003.04402.x","article-title":"Determining the cause of death in randomized screening trial(s) for prostate cancer","volume":"92","author":"De Koning","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.12.004_b0045","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ijc.23126","article-title":"Assessment of causes of death in a prostate cancer screening trial","volume":"122","author":"Makinen","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2025.12.004_b0050","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/sim.7297","article-title":"Causal inference in survival analysis using pseudo-observations","volume":"36","author":"Andersen","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2025.12.004_b0055","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/aje\/kwx051","article-title":"Flexible mediation analysis with multiple mediators","volume":"186","author":"Steen","year":"2017","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.euo.2025.12.004_b0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.euo.2023.08.011","article-title":"ERSPC Rotterdam Study Group. From screening to mortality reduction: an overview of empirical data on the patient journey in European Randomized Study of Screening for Prostate Cancer Rotterdam after 21 years of follow-up and a reflection on quality of life","volume":"7","author":"Hogenhout","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.004_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2023.02.013","article-title":"The patient journey from randomization to detection of prostate cancer and death: results from ERSPC Rotterdam","volume":"51","author":"Remmers","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.12.004_b0070","doi-asserted-by":"crossref","first-page":"6.398.e7","DOI":"10.1016\/j.urolonc.2025.02.023","article-title":"Do differences in secondary treatment explain mortality impact of prostate cancer screening? A randomized screening trial","volume":"43","author":"Lampela","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.004_b0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2017.01.048","article-title":"Estimate of opportunistic prostate specific antigen testing in the Finnish randomized study of screening for prostate cancer","volume":"198","author":"Kilpel\u00e4inen","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.12.004_b0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.euf.2017.07.007","article-title":"Impact of prostatic-specific antigen threshold and screening interval in prostate cancer screening outcomes: comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer centres","volume":"5","author":"Saarim\u00e4ki","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.12.004_b0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canep.2016.11.005","article-title":"What explains the differences between centres in the European screening trial? A simulation study","volume":"46","author":"Nevalainen","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.euo.2025.12.004_b0090","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.eururo.2019.04.007","article-title":"The impact of design and performance in prostate-specific antigen screening: differences between ERSPC centers","volume":"76","author":"Heijnsdijk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.004_b0095","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ijc.32129","article-title":"Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: analysis of the Finnish randomized study of screening for prostate cancer","volume":"145","author":"Lindberg","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2025.12.004_b0100","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/ijc.25278","article-title":"Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)","volume":"127","author":"Kerkhof","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2025.12.004_b0105","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/JU.0000000000002835","article-title":"Prostate specific antigen and biopsy contamination in the G\u00f6teborg-1 randomized, population-based, prostate cancer screening trial","volume":"208","author":"Stinesen Kollberg","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.12.004_b0110","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/00365599.2011.559950","article-title":"High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm","volume":"45","author":"Godtman","year":"2011","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.euo.2025.12.004_b0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/bjc.2016.378","article-title":"Impact of cause of death adjudication on the results of the European prostate cancer screening trial","volume":"116","author":"Walter","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2025.12.004_b0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.euros.2024.10.021","article-title":"Assessing the cause of death for men with prostate cancer using official mortality statistics or a dedicated cause of death committee: results from 30-year ERSPC Rotterdam data","volume":"71","author":"Remmers","year":"2025","journal-title":"Eur Urol Open Sci"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112500330X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112500330X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T20:35:14Z","timestamp":1767818114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112500330X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"alternative-id":["S258893112500330X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.004","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Causal and Noncausal Components of Screening on Prostate Cancer Mortality: A Mediation Analysis from the Dutch, Finnish, and Swedish Centers of the European Randomized Study of Screening for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}